Our founders are building beyond the pre-defined edges of human health. Through the convergence of technology and biology and the reimagining of healthcare, we’re the first call for bold entrepreneurs pushing boundaries and leading the way towards better care for all.
From seed financing through IPO and beyond, we’re partnering with a new generation of determined, multidisciplinary entrepreneurs across the entire company‑building journey. Together we are building iconic companies that are radically transforming how we diagnose, treat, and manage disease, while building the healthcare system of tomorrow.
Curious about The Edge? Learn More
Insights from leaders at OpenAI, Microsoft, Anthropic, Databricks, Character.AI, Roblox, insitro, and Figma on where we are, where we're going, and the open questions for building the next wave of AI.
Daphne Koller, founder and CEO of insitro, discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.
As we strive to find and support the most ambitious life sciences founders, we also work to connect these founders with exceptional advisors who have traveled the journey before.
10 founders on how tech will make our healthcare system more intuitive, efficient, and cost-effective.
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.
Catalysts. Conveners. Connective Tissue. Bringing tech-enabled innovations to patients through ecosystem partnerships.
We’re former founders, operators, and entrepreneurs. We’re MDs, PhDs, scientists, and technologists. We bring the know-how and networks of five full operating teams and deep expertise from across our consumer, enterprise, and fintech practices to help founders find their edge.
We win as one team, and we win big.
See Full Team
Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.
